September 2024's Top Growth Companies With High Insider Ownership

As global markets experience mixed performance, with U.S. stocks ending the week on a varied note and European inflation nearing central bank targets, investors are keenly observing growth companies with high insider ownership. Such companies often indicate strong confidence from those closest to the business, making them attractive in an environment where economic resilience and consumer spending are showing promising signs.

Top 10 Growth Companies With High Insider Ownership

Name	Insider Ownership	Earnings Growth
Lavvi Empreendimentos Imobiliários (BOVESPA:LAVV3)	11.9%	20.3%
Atlas Energy Solutions (NYSE:AESI)	29.1%	42.1%
Clinuvel Pharmaceuticals (ASX:CUV)	13.6%	27.4%
On Holding (NYSE:ONON)	28.4%	24.4%
KebNi (OM:KEBNI B)	37.8%	86.1%
Calliditas Therapeutics (OM:CALTX)	12.7%	51.9%
Credo Technology Group Holding (NasdaqGS:CRDO)	14.1%	60.9%
Adocia (ENXTPA:ADOC)	11.9%	63%
Plenti Group (ASX:PLT)	12.8%	106.4%
EHang Holdings (NasdaqGM:EH)	32.8%	78.8%

Click here to see the full list of 1508 stocks from our Fast Growing Companies With High Insider Ownership screener.

Let's dive into some prime choices out of the screener.

Zhejiang Weiming Environment Protection (SHSE:603568)

Simply Wall St Growth Rating: ★★★★★★

Overview: Zhejiang Weiming Environment Protection Co., Ltd. operates in the environmental protection industry and has a market cap of CN¥30.90 billion.

Operations: Zhejiang Weiming Environment Protection Co., Ltd. generates revenue primarily from its industrial segment, amounting to CN¥7.24 billion.

Insider Ownership: 24%

Revenue Growth Forecast: 29.9% p.a.

Zhejiang Weiming Environment Protection demonstrates robust growth prospects with earnings forecasted to grow 23.74% annually and revenue expected to rise by 29.9% per year, outpacing the market. Recent H1 2024 results showed sales of CNY 4.11 billion and net income of CNY 1.42 billion, reflecting significant year-over-year increases. The company's Price-To-Earnings ratio of 12.7x indicates good value compared to the CN market average, although its dividend coverage is weak.

• Navigate through the intricacies of Zhejiang Weiming Environment Protection with our comprehensive analyst estimates report here.
• Our valuation report unveils the possibility Zhejiang Weiming Environment Protection's shares may be trading at a discount.

KEBODA TECHNOLOGY (SHSE:603786)

Simply Wall St Growth Rating: ★★★★★☆

Overview: KEBODA TECHNOLOGY Co., Ltd. manufactures and sells automotive electronics and related products for the automotive industry in China, with a market cap of CN¥17.62 billion.

Operations: KEBODA TECHNOLOGY Co., Ltd. generates revenue primarily from the manufacture and sale of automotive electronics and related products within China's automotive sector.

Insider Ownership: 12.8%

Revenue Growth Forecast: 22.2% p.a.

KEBODA TECHNOLOGY is poised for significant growth with earnings forecasted to increase by 26.9% annually and revenue expected to rise by 22.2% per year, outpacing the CN market. The company recently reported H1 2024 sales of CNY 2.74 billion and net income of CNY 371.57 million, reflecting strong year-over-year growth. Trading at a value below its estimated fair price and lacking recent insider trading activity, KEBODA remains a compelling growth opportunity despite low dividend coverage and projected ROE challenges.

• Click to explore a detailed breakdown of our findings in KEBODA TECHNOLOGY's earnings growth report.
• According our valuation report, there's an indication that KEBODA TECHNOLOGY's share price might be on the expensive side.

Eyebright Medical Technology (Beijing) (SHSE:688050)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Eyebright Medical Technology (Beijing) Co., Ltd. operates in the medical technology sector, focusing on innovative healthcare solutions, with a market cap of approximately CN¥14.19 billion.

Operations: Eyebright Medical Technology (Beijing) Co., Ltd. generates its revenue primarily from innovative healthcare solutions within the medical technology sector.

Insider Ownership: 21.5%

Revenue Growth Forecast: 27.5% p.a.

Eyebright Medical Technology (Beijing) is set for robust growth, with earnings projected to rise 27.91% annually and revenue expected to grow 27.5% per year, both surpassing market averages. Recent H1 2024 results showed sales of CNY 685.72 million and net income of CNY 208.04 million, indicating strong performance year-over-year. The stock trades at a significant discount to its estimated fair value, despite low forecasted ROE and no recent insider trading activity reported.

• Get an in-depth perspective on Eyebright Medical Technology (Beijing)'s performance by reading our analyst estimates report here.
• The valuation report we've compiled suggests that Eyebright Medical Technology (Beijing)'s current price could be quite moderate.

Summing It All Up

• Embark on your investment journey to our 1508 Fast Growing Companies With High Insider Ownership selection here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com